A non-interventional study to examine patient characteristics and drug utilization patterns in migraine patients treated with prophylactic drugs in Nordic countries

Study type

• Study topic:
  Disease /health condition

  Human medicinal product
• Study type:
  Non-interventional study
• Scope of the study:
  Drug utilisation

Non-interventional study

• Non-interventional study design:
  Cohort

Study drug and medical condition

• Name of medicine:
  AIMOVIG
• Study drug International non-proprietary name (INN) or common name:
  ERENUMAB
• Anatomical Therapeutic Chemical (ATC) code:
  (N02CD01) erenumab

  erenumab
• Medical condition to be studied:
  Migraine

Population studied

• Age groups:
  Adults (18 to < 46 years)

  Adults (46 to < 65 years)

  Adults (65 to < 75 years)

  Adults (75 to < 85 years)

  Adults (85 years and over)
• Special population of interest:
  Pregnant women
• Estimated number of subjects:
  10

Study design details

• Main study objective:
  The primary objective of this study was to describe utilization of erenumab among patients with migraine
• Data analysis plan:
  All analyses were descriptive. Appropriate summary descriptive statistics were used for categorical and continuous variables. ; Cumulative incidences were used to summarize utilization of erenumab. ; Rates and cumulative incidences were used to describe the CV endpoints during the follow-up.